Palbociclib is a prescription anticancer medicine. The exact product formulation, manufacturer, and pack size should be confirmed before publishing the listing.
What Is Palbociclib 125 mg?
Palbociclib 125 mg is an oral targeted anticancer medicine belonging to the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor class.
It is used in combination with endocrine therapy for certain patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer.
Palbociclib works by inhibiting CDK4 and CDK6 enzymes, which are involved in regulating cell division.
By blocking these enzymes, palbociclib can slow the progression of susceptible cancer cells through the cell cycle.
Palbociclib is generally prescribed in combination with medicines such as:
- Letrozole
- Anastrozole
- Exemestane
- Fulvestrant
- Other endocrine therapy when supported by applicable prescribing information
The exact combination depends on the patient’s diagnosis, previous treatment, menopausal status, and local regulatory approvals.
Important: Palbociclib is not a general cancer cure and is not appropriate for every type of breast cancer. It must be prescribed and monitored by an oncology specialist.
How Does Palbociclib 125 mg Work?
1. Inhibits CDK4 and CDK6 Enzymes
Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6.
These enzymes help regulate progression through the cell cycle.
2. Blocks Cell-Cycle Progression
CDK4 and CDK6 normally contribute to phosphorylation of the retinoblastoma (Rb) protein.
Inhibiting these enzymes reduces Rb phosphorylation in susceptible cells.
3. Causes G1 Cell-Cycle Arrest
Palbociclib can prevent susceptible cancer cells from progressing from the G1 phase into the S phase of the cell cycle.
4. Slows Cancer Cell Proliferation
By interfering with cell-cycle progression, palbociclib may slow the multiplication of certain breast cancer cells.
5. Complements Endocrine Therapy
Hormone receptor-positive breast cancers may depend on estrogen signaling for growth.
Combining palbociclib with endocrine therapy targets both hormonal signaling and cell-cycle progression.
6. Helps Delay Disease Progression
Clinical studies have demonstrated improvements in progression-free survival in selected patient populations.
7. Supports Disease Management
Palbociclib may help control advanced or metastatic breast cancer when used in an appropriate combination regimen.
Important: Palbociclib is not guaranteed to shrink tumors or produce the same treatment response in every patient.
Uses of Palbociclib 125 mg
1. HR-Positive, HER2-Negative Advanced Breast Cancer
Palbociclib is used with endocrine therapy in selected patients with advanced HR-positive, HER2-negative breast cancer.
2. Metastatic Breast Cancer
Palbociclib may be prescribed for eligible patients whose HR-positive, HER2-negative breast cancer has spread beyond the breast.
3. First-Line Endocrine-Based Treatment
Palbociclib may be combined with an aromatase inhibitor as an initial endocrine-based treatment for eligible patients with advanced or metastatic disease.
4. Treatment After Disease Progression
Palbociclib may be combined with fulvestrant in selected patients whose disease has progressed following endocrine therapy.
5. Targeted Cancer Therapy
Palbociclib targets CDK4/6 enzymes involved in cancer cell proliferation.
6. Combination With Aromatase Inhibitors
Palbociclib may be used with an aromatase inhibitor according to approved treatment protocols.
7. Combination With Fulvestrant
Palbociclib may be used with fulvestrant for eligible patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
8. Progression-Free Survival Support
In appropriate patients, palbociclib-containing regimens may extend the time before disease progression compared with certain endocrine therapy regimens alone.
Important: Treatment eligibility and approved indications vary by country and may change as new clinical evidence becomes available.
How to Take Palbociclib 125 mg
Palbociclib should be taken exactly as prescribed by an oncology specialist.
General Administration Instructions
- Confirm the prescribed formulation and strength.
- Follow the oncologist’s treatment schedule.
- Take the medicine at approximately the same time each day.
- Swallow capsules or tablets whole.
- Do not crush, chew, or open the dosage form.
- Follow the food instructions for the specific formulation.
- Avoid grapefruit and grapefruit juice.
- Do not change the dose without medical advice.
- Attend scheduled blood tests and oncology appointments.
- Report fever, signs of infection, or unusual symptoms promptly.
Recommended Dosage
A commonly recommended adult starting dose is:
125 mg orally once daily for 21 consecutive days, followed by 7 days without palbociclib, forming a 28-day treatment cycle.
Palbociclib is administered with the prescribed endocrine therapy.
| Treatment Detail | General Reference |
|---|---|
| Starting Dose | 125 mg once daily |
| Treatment Days | Days 1–21 |
| Rest Period | Days 22–28 |
| Cycle Duration | 28 days |
| Common Dose Reduction Levels | 100 mg and 75 mg |
| Combination Therapy | As prescribed by the oncologist |
Important: This is a general labeled dosing schedule, not a personalized prescription. Dose interruptions or reductions may be necessary because of adverse effects, drug interactions, or organ impairment.
Capsules vs. Tablets
Palbociclib is available in capsule and tablet formulations in certain markets.
Capsules: Generally taken with food according to the product’s prescribing instructions.
Tablets: May generally be taken with or without food.
Always follow the directions for the specific formulation.
What If a Dose Is Missed?
If a dose is missed, do not take an additional dose that day.
Take the next prescribed dose at the usual time.
What If Vomiting Occurs?
Do not take an additional dose after vomiting.
Take the next scheduled dose at the usual time.
Can Palbociclib Be Stopped Suddenly?
Do not interrupt or discontinue treatment without oncology guidance unless urgent medical care is required for a serious reaction.
How Long Does Palbociclib 125 mg Take to Work?
Palbociclib begins inhibiting CDK4/6 activity after administration, but treatment response is assessed over time.
The oncologist may evaluate response through:
- Clinical examinations
- Imaging studies
- Laboratory investigations
- Disease-related symptoms
- Treatment tolerance
- Evidence of disease progression
There is no single guaranteed timeframe for tumor response.
Palbociclib treatment may continue for multiple cycles as long as the patient benefits and adverse effects remain manageable.
Common Side Effects
Possible side effects include:
- Neutropenia
- Leukopenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
- Mouth sores
- Hair thinning
- Reduced appetite
- Infections
- Weakness
- Vomiting
- Rash
- Changes in liver enzymes
Neutropenia, a reduction in certain white blood cells, is one of the most important adverse effects associated with palbociclib.
Potentially Harmful Effects & Serious Health Risks
1. Severe Neutropenia
Palbociclib can significantly reduce neutrophil counts, increasing susceptibility to infections.
2. Serious Infections
Patients with low white blood cell counts may develop serious infections.
Fever of 38°C (100.4°F) or higher during cancer treatment requires immediate contact with the oncology team or urgent medical assessment.
3. Febrile Neutropenia
Fever associated with a low neutrophil count is a potentially serious medical complication.
4. Anemia
Palbociclib may reduce red blood cell counts, causing fatigue, weakness, or shortness of breath.
5. Thrombocytopenia
Reduced platelet counts may increase the risk of bruising or bleeding.
6. Interstitial Lung Disease (ILD) / Pneumonitis
Rare but potentially severe or fatal lung inflammation has been reported with CDK4/6 inhibitors, including palbociclib.
New or worsening cough, breathing difficulty, or shortness of breath requires prompt medical evaluation.
7. Liver-Related Abnormalities
Elevated liver enzymes and other liver-related abnormalities may occur.
8. Severe Allergic Reactions
Serious hypersensitivity reactions may occur.
9. Embryo-Fetal Toxicity
Palbociclib may harm an unborn baby.
Pregnancy prevention precautions are required during treatment and for the recommended period afterward.
10. Drug Interactions
Strong CYP3A inhibitors may increase palbociclib exposure, while strong CYP3A inducers may reduce its effectiveness.
Contraindications & Precautions
1. Low White Blood Cell Count
Patients with neutropenia require careful blood count monitoring and possible dose modification.
2. Active Infection
Patients should inform their oncologist about fever, infection symptoms, or other signs of illness.
3. Lung Disease
Patients with existing lung conditions should report new or worsening respiratory symptoms.
4. Liver Impairment
Severe liver impairment may require dose adjustment.
5. Kidney Impairment
Patients with kidney disease should inform their oncologist. Data in patients requiring hemodialysis are limited.
6. Pregnancy
Palbociclib can cause fetal harm and should not be used during pregnancy unless a specialist determines otherwise in an exceptional clinical situation.
7. Breastfeeding
Breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose under U.S. labeling.
8. Contraception for Female Patients
Females of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose.
9. Contraception for Male Patients
Males with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
10. Fertility
Palbociclib may impair male fertility.
11. Grapefruit
Avoid grapefruit and grapefruit juice because they may increase palbociclib exposure.
12. Drug Interactions
Potentially relevant medicines include:
- Clarithromycin
- Ketoconazole
- Itraconazole
- Rifampin
- Carbamazepine
- Phenytoin
- Certain antiviral medicines
- Other strong CYP3A inhibitors or inducers
13. Herbal Supplements
St. John’s wort may reduce palbociclib exposure and should generally be avoided.
14. Blood Count Monitoring
Complete blood counts are required before treatment, at the beginning of each cycle, and at additional intervals specified by the oncologist.
15. Dose Modification
Dose interruptions or reductions may be required for severe adverse reactions.
16. Treatment Adherence
Follow the 21-day treatment and 7-day rest schedule exactly as prescribed.
17. Prescription Supervision
Palbociclib should only be prescribed by clinicians experienced in anticancer treatment.
18. Medical Monitoring
Healthcare professionals may monitor:
- Complete blood count
- Neutrophil count
- Platelet count
- Hemoglobin
- Liver function
- Kidney function when indicated
- Signs of infection
- Respiratory symptoms
- Medication interactions
- Imaging results
- Treatment response
- Disease progression
- Adverse reactions
Advantages
- Targeted anticancer medicine.
- Selective CDK4/6 inhibition.
- Used for HR-positive, HER2-negative advanced breast cancer.
- Used for selected metastatic breast cancer patients.
- Oral administration.
- Combines with endocrine therapy.
- May improve progression-free survival in eligible patients.
- Established clinical use in appropriate treatment settings.
- Predictable 28-day treatment cycle.
- Dose adjustment options are available.
- May delay disease progression in selected patients.
- Can be included in individualized oncology treatment plans.
Disadvantages / Limitations
- May cause severe neutropenia.
- May increase infection risk.
- May cause anemia.
- May cause thrombocytopenia.
- May cause fatigue.
- May cause nausea.
- May cause diarrhea.
- May cause mouth sores.
- May cause hair thinning.
- May cause serious lung inflammation.
- May cause liver enzyme abnormalities.
- Requires frequent blood tests.
- Requires oncology supervision.
- May interact with other medicines.
- Can harm an unborn baby.
- Not suitable for every breast cancer subtype.
- Not a guaranteed cure for cancer.
- May require dose interruptions or reductions.
- Treatment resistance or disease progression may occur.
Important Notes
Generic Name: Palbociclib.
Active Ingredient: Palbociclib 125 mg.
Strength: 125 mg.
Dosage Form: Oral Capsules or Tablets.
Drug Class: CDK4/6 Inhibitor.
Therapeutic Category: Targeted Anticancer Medicine.
Primary Use: Selected HR-positive, HER2-negative advanced or metastatic breast cancer.
Mechanism of Action: Inhibition of cyclin-dependent kinases 4 and 6.
Common Treatment Schedule: 21 days of treatment followed by 7 days off.
Administration Route: Oral.
Combination Therapy: Used with prescribed endocrine therapy.
Major Warning: Severe neutropenia and infection risk.
Lung Warning: Risk of interstitial lung disease and pneumonitis.
Pregnancy Warning: May cause fetal harm.
Monitoring: Regular complete blood counts and oncology follow-up.
Storage: Follow manufacturer instructions.
Frequently Asked Questions
1. What is Palbociclib 125 mg used for?
Palbociclib is used with endocrine therapy for selected patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
2. Is Palbociclib a chemotherapy medicine?
Palbociclib is a targeted anticancer medicine rather than conventional cytotoxic chemotherapy.
3. How does Palbociclib work?
It inhibits CDK4 and CDK6 enzymes involved in cell-cycle progression.
4. Can Palbociclib treat breast cancer?
Yes. It is used for specific HR-positive, HER2-negative advanced or metastatic breast cancers.
5. Can Palbociclib treat all types of cancer?
No. Its approved uses are limited to specific cancer indications.
6. Is Palbociclib used alone?
For its established breast cancer indications, palbociclib is used in combination with endocrine therapy.
7. What is the usual Palbociclib 125 mg treatment schedule?
A common schedule is 125 mg once daily for 21 days, followed by 7 days without palbociclib.



































































Reviews
There are no reviews yet.